Logo of Invex Therapeutics (ASX:IXC)Latest Invex Therapeutics (ASX:IXC) News

Page 2
Page 2 of 3

Healthcare Wrap - Week 4 (19 Jan -> 23 Jan) 2026

A small-cap healthcare rally had a clear centre: distribution deals, US regulatory steps, and big cheques. Osteopore, Echo IQ and Anteris led the week, while a handful of names slipped despite solid operational updates.
Logan Eniac
25 Jan 2026

Invex Therapeutics Advances Alzheimer’s Research Amid Board Shakeup and $4.5M Cash Reserve

Invex Therapeutics reports promising new data from its collaboration with Tessara Therapeutics on Exenatide’s potential in Alzheimer’s disease, alongside significant board changes and a solid cash position at quarter’s end.
Ada Torres
22 Jan 2026

Invex Therapeutics Resumes Trading After Key Board Appointments

Invex Therapeutics Ltd has had its trading suspension lifted following an announcement of new board and officer appointments, signaling a fresh chapter for the biotech company.
Ada Torres
10 Nov 2025

Invex Therapeutics Refreshes Board and Leadership Amid Strategic Reset

Invex Therapeutics has appointed two new non-executive directors and joint company secretaries, signaling a refreshed governance structure alongside a change of company address.
Ada Torres
10 Nov 2025

Invex Therapeutics Suspended from ASX Over Board Shortfall

Invex Therapeutics Ltd has been suspended from trading on the ASX due to a failure to maintain the minimum number of directors required by law. The suspension will remain until the company rectifies its governance structure and complies with listing rules.
Ada Torres
7 Nov 2025

Invex Therapeutics Halts Two Neurological Deals Amid Board Turmoil

Invex Therapeutics has ended negotiations on two neurological asset acquisitions following due diligence setbacks and shareholder disputes, while advancing R&D collaborations and managing financial stability.
Ada Torres
3 Oct 2025

Invex Therapeutics Resumes Trading After Major Acquisition Reveal

Invex Therapeutics Ltd has had its trading suspension lifted following the announcement of a material acquisition, signaling a pivotal moment for the biotech company.
Ada Torres
30 Sept 2025

Invex Therapeutics Halts Acquisition Talks Amid Boardroom Turmoil

Invex Therapeutics reveals the collapse of confidential acquisition negotiations following shareholder unrest and potential board changes, clarifying recent unusual trading activity.
Ada Torres
30 Sept 2025

Invex Therapeutics Halts Acquisition Amid Boardroom Turmoil

Invex Therapeutics has discontinued exclusive negotiations to acquire a rare neurological disease company due to board instability triggered by a shareholder requisition notice. Despite this setback, the company remains committed to diversifying its neurological treatment portfolio.
Ada Torres
30 Sept 2025

Invex Therapeutics Halts Trading Ahead of Major Acquisition Reveal

Invex Therapeutics has voluntarily suspended trading on the ASX pending a significant acquisition announcement and responses to a price query. The suspension is expected to last until the announcement or early next week.
Ada Torres
25 Sept 2025

Invex Therapeutics Narrows Loss, Unveils Alzheimer’s Breakthrough in Exenatide Research

Invex Therapeutics reports a significantly reduced net loss for FY25, driven by lower R&D costs after closing its Phase III trial, while advancing promising pre-clinical Alzheimer’s research through a collaboration with Tessara Therapeutics.
Ada Torres
11 Aug 2025

Invex Therapeutics Expands Alzheimer’s Research and Secures Orphan Drug Renewals

Invex Therapeutics has broadened its collaboration with Tessara Therapeutics to explore Exenatide’s potential in Alzheimer’s disease, while successfully renewing key orphan drug designations in Europe and the US.
Ada Torres
23 July 2025